Topical TDM-105795 solution is used for the treatment of androgenetic alopecia. Credit: Towfiqu barbhuiya on Unsplash.

Technoderma Medicines has started dosing patients in a Phase II study of topical TDM-105795 solution for the treatment of androgenetic alopecia (AGA).

The multi-dose, vehicle-controlled, parallel group, double-blind, randomised study will enrol male subjects with AGA.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study will assess the safety, efficacy and pharmacokinetics of two different active formulation strengths of TDM-105795 for 16 weeks against a placebo.

Technoderma Medicines CEO Zengquan Wang said: “We have assets in multiple phases of clinical development and anticipate bringing other preclinical pipeline products to clinical testing in subsequent years.

“We have demonstrated that the company can sustainably produce a robust portfolio of dermatology drug candidates.”

Participants for the study are selected from nearly 12 US sites, under an open IND with FDA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Technoderma Medicines chief medical officer Arthur Bertolino said: “We expect the current study design to support proof-of-concept regarding hair growth efficacy and to guide choice of formulation strength(s) appropriate for late stage clinical development.

“Observation of meaningful quantitative data regarding hair counts and global photographic assessments of hair growth will enable us to anchor the programme.”

Apart from the AGA programme, the company is involved in other programmes for developing new therapies for atopic dermatitis, psoriasis and lupus erythematosus.

The company’s Phase IIa trial of TDM-105795 for AGA is also underway. In addition, the company is testing JAK1/TYK2 inhibitor TDM-180935 for atopic dermatitis in a Phase I study.